Advancements in aptamer development technologies, increasing R&D expenditure, and the rising number of companies investing in this market are some of the key driving factors responsible for the growth of the aptamers market.
- Numerous advantages offered by these small molecules, in comparison to established antibodies, have also led to higher demand for these molecules across a diverse range of medical applications. They are chemically synthesized, which eliminates batch-to-batch variation and demands less time for development. Along with this, continuous advancement in technologies is expected to stimulate the market growth.
- However, many aptamers have failed to meet the requisite safety and efficacy standards in clinical studies. Thus, companies had to terminate their clinical investigation during late-stage clinical studies. This factor is likely to affect the growth of this market negatively. In addition, other factors, such as low awareness about these technologies in middle- and low-income countries and inadequate regulatory structure, may hamper the overall market growth.
Key Market Trends
The Diagnostics Segment is Expected to Witness a Healthy Growth
Appropriate diagnosis is the most crucial factor for the treatment of diseases, especially viral diseases. Over the past few years, aptamer technology has observed a significant rise in its demand and usage all across the world. It has been used in a wide range of diagnostic as well as therapeutic applications; several strategies are currently being explored, in a definitive or conclusive way, using aptamers against virus proteins. From a diagnostic point of view, aptamers are presently being designed as a bio-recognition element in a variety of diagnostic systems in order to detect viral proteins, either in the blood (serum or plasma) or in the infected cells.
North America Dominates the Market and is Expected to do the Same in the Forecast Period
The North American region dominates the aptamers market due to rapid technological advancements and high investment and funding to support the development of aptamers. The United States has been the hub of all major R&D activities related to aptamers. The first aptamer therapeutic product ‘’Macugen’’ was approved in 2004 by the US FDA (United States Food and Drugs Administration).
In the country, R&D happens to be the most active area of application of aptamers. A significant proportion of demand is seen in research applications, which is also responsible for generating revenues in the market. Furthermore, the growing acceptance of personalized medicine is also one of the major factors driving the growth of the market. Aptamers have evolved rapidly in the past ten years, and aptamers have targeted a range of molecules involved in tumor progression and metastasis, present at different sites.
The aptamers market is highly competitive and consists of a number of major players. Companies, like AM Biotechnologies LLC, Aptagen LLC, Aptamer Sciences Inc., Aptamer Group, Aptus Biotech S.L., Base Pair Biotechnologies Inc., NOXXON Pharma, SomaLogic Inc., TriLink BioTechnologies Inc., and Vivonics Inc., among others, hold the substantial share in the aptamers market.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support